{
    "root": "35ac3ffd-466d-1fa8-e063-6294a90a38e3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Diclofenac Sodium",
    "value": "20250521",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "DICLOFENAC SODIUM",
            "code": "QTG126297Q",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4509"
        }
    ],
    "indications": {
        "text": "carefully consider potential benefits risks diclofenac sodium delayed-release tablets treatment options deciding diclofenac sodium delayed-release tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( : gastrointestinal bleeding , ulceration perforation ) . diclofenac sodium delayed-release tablets indicated : relief signs symptoms osteoarthritis relief signs symptoms rheumatoid arthritis acute long-term relief signs symptoms ankylosing spondylitis",
        "doid_entities": [
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "carefully consider potential benefits risks diclofenac sodium delayed-release tablets treatment options deciding diclofenac sodium delayed-release tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( : gastrointestinal bleeding , ulceration , perforation ) . observing response initial therapy diclofenac sodium delayed-release tablets , dose frequency adjusted suit individual patient \u2019 needs . relief osteoarthritis , recommended 100 150 mg/day divided doses ( 50 mg twice day three times day , 75 mg twice day ) . relief rheumatoid arthritis , recommended 150 200 mg/day divided doses ( 50 mg three times day four times day , 75 mg twice day ) . relief ankylosing spondylitis , recommended 100 125 mg/day , administered 25 mg four times day , extra 25 mg dose bedtime necessary . different formulations diclofenac ( diclofenac sodium enteric-coated tablets ; diclofenac sodium extended-release tablets ; diclofenac potassium immediate-release tablets ) necessarily bioequivalent even milligram strength .",
        "doid_entities": [
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "75 mg : round , light brown , enteric-coated tablets 60760-090-15 bottles 15 60760-090-20 bottles 20 60760-090-30 bottles 30 60760-090-60 bottles 60 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ( usp controlled room temperature ) . protect moisture . dispense tight , light-resistant container .",
    "adverseReactions": "diclofenac sodium delayed-release tablets contraindicated following patients . known hypersensitivity ( e.g . , anaphylactic serious skin ) diclofenac components product ( : anaphylactic , serious skin ) . history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients ( : anaphylactic reaction , exacerbation asthma related aspirin sensitivity ) . setting coronary artery bypass graft ( cabg ) surgery ( : cardiovascular thrombotic events ) .",
    "indications_original": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n       \n \n  \n                        WARNINGS: Gastrointestinal Bleeding, Ulceration and Perforation\n                     ).\n      \n\n \n                  Diclofenac sodium delayed-release tablets are indicated:\n                  \n                     For relief of the signs and symptoms of osteoarthritis\n                     For relief of the signs and symptoms of rheumatoid arthritis\n                     For acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis",
    "contraindications_original": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n       \n \n  \n                        WARNINGS: Gastrointestinal Bleeding, Ulceration, and Perforation\n                     ).\n      \n\n \n                  After observing the response to initial therapy with diclofenac sodium delayed-release tablets, the dose and frequency should be adjusted to suit an individual patient\u2019s needs.\n                  For the relief of osteoarthritis, the recommended dosage is 100 to 150 mg/day in divided doses (50 mg twice a day or three times a day, or 75 mg twice a day).\n                  For the relief of rheumatoid arthritis, the recommended dosage is 150 to 200 mg/day in divided doses (50 mg three times a day or four times a day, or 75 mg twice a day).\n                  For the relief of ankylosing spondylitis, the recommended dosage is 100 to 125 mg/day, administered as 25 mg four times a day, with an extra 25 mg dose at bedtime if necessary.\n                  Different formulations of diclofenac (diclofenac sodium enteric-coated tablets; diclofenac sodium extended-release tablets; diclofenac potassium immediate-release tablets) are not necessarily bioequivalent even if the milligram strength is the same.",
    "warningsAndPrecautions_original": "75 mg: round, light brown, enteric-coated tablets \n  \n                        \n                     \n                  \n                  \n                  \n                  \n                  \n                     60760-090-15 BOTTLES OF 15\n                  \n                  \n                     60760-090-20 BOTTLES OF 20\n                  \n                  \n                     60760-090-30 BOTTLES OF 30\n                  \n                  \n                     60760-090-60 BOTTLES OF 60\n                  \n                  \n                  \n                  \n                  \n                  \n                  \n                  \n                  \n                  \n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) (see USP Controlled Room Temperature). Protect from moisture.\n                  \n                  \n                  Dispense in a tight, light-resistant container.",
    "adverseReactions_original": "Diclofenac sodium delayed-release tablets are contraindicated in the following patients.\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see \n        \n  \n   \n                           WARNINGS: Anaphylactic Reactions\n                        , \n        \n  \n   \n                           Serious Skin Reactions\n                        ).\n       \n \n  \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (see \n        \n  \n   \n                           WARNINGS: Anaphylactic\nReaction\n                        , \n        \n  \n   \n                           Exacerbation of Asthma Related to Aspirin Sensitivity\n                        ).\n       \n \n  \n                     In the setting of coronary artery bypass graft (CABG) surgery (see \n        \n  \n   \n                           WARNINGS: Cardiovascular Thrombotic\nEvents).",
    "drug": [
        {
            "name": "Diclofenac Sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4509"
        }
    ]
}